In April, 2019, Hangzhou Qiantang New Area, including Hangzhou Dajiangdong Industry Cluster Zone and Hangzhou Economic and Technological Development Area, was approved to establish by Zhejiang Provincial People’s Government. The Area boasts three state-level honors—Hangzhou Economic and Technological Development Area, Hangzhou Comprehensive Bonded Area and Linjiang High-tech Industrial Development Zone.
　　 Hangzhou Qiantang New Area has gathered lots of key enterprises, such as Pfizer, MSD, Abbott, Huadong Medicine, Mary kay and so on. Besides, there are a number of major projects under construction, including Huahai Medicine, Jiuzhou, AllTest Biotech, etc. In the future, Hangzhou Qiantang New Area will focus on bio-pharmaceutical, medical apparatus and instruments, biomedical engineering and medical big data, aiming to create an industry cluster with output value of 100 bn Yuan.

       Massachusetts Gov. Charlie Baker (R) in June recommitted his state to helping grow its biopharma industry, anchored in Boston and Cambridge, MA, by reauthorizing the Massachusetts Life Sciences Initiative. The $623 million in bonds and tax credits authorized over five years is smaller than the $1 billion, decade-long measure enacted in 2007 by then-Gov. Deval Patrick (D), though the state says it remains as focused as ever on industry growth.
　　Eighteen of the top 20 biopharmas have a major presence in Boston/Cambridge, and the region continues to welcome companies of all sizes: Alexandria Real Estate Equities this fall will open its second LaunchLabs startup accelerator in Cambridge, as Takeda Pharmaceutical prepares to move its U.S. HQ to Boston/Cambridge (See Chicagoland above). Cambridge-based Moderna Therapeutics in July opened a $110 million site in suburban Norwood, MA. Cambridge this year welcomed expansion plans by AbbVie, among numerous companies, and the openings of Fujifilm Diosynth’s new collaboration center and Thermo Fisher’s U.S. Precision Medicine Science Center.

       KBIC, the largest biomedical cluster in Japan, is the innovation arm of the City of Kobe to foster innovation and collaboration among its members and affiliates to ensure a thriving biomedical industry.
　　KBIC currently boasts a concentrated network of close to about 370 companies, universities and research institutes, and specialized hospitals, in addition to a growing network of international biocluster partners, who are all focused on the development of innovative medical technology and pioneering discoveries through collaboration. Leading institutes at KBIC include Riken Center for Biosystems Dynamics Research, Japan’s largest comprehensive research organization. Our corporate members range from promising startups, such as Bio Palette, to leading multinational healthcare giants, such as Boehringer Ingelheim. Click here for more details.

       Planing area 79.7 square kilometers, Through strong innovation atmosphere, a plurality of talent accumulation, powerful innovation platform, ZJ Park attracted a large number of top hi-tech enterprises and small-mediun sized innovative enterprises, and is the birth place of new technology , new pattern and new format.